KISSEI PHARMACEUTICAL CO., LTD.
4547・Prime Market・Pharmaceuticals
Governance
The company has adopted a Board of Corporate Auditors structure, comprising 12 directors (including 4 outside directors) and 4 corporate auditors (including 2 outside auditors). As advisory bodies to the Board of Directors, it has established a Nomination and Compensation Deliberation Committee, a Risk Management Committee, a Compliance Committee, and a Sustainability Promotion Committee, aiming to enhance management transparency and oversight functions.
Risk Management
The company has established a Risk Management Committee and a Compliance Committee as advisory bodies to the Board of Directors, building a company-wide risk management framework based on the "Risk Management Regulations." Sustainability-related risks are evaluated at least once a year by the Sustainability Promotion Committee, and a system has been put in place to deliberate and report on these matters to the Board of Directors and the Board of Corporate Auditors.
Shareholder Returns
Under a progressive dividend policy, the annual dividend for FY2026 (ending March 2026) is planned at ¥160 per share (interim ¥60 + year-end ¥100, including a ¥40 commemorative dividend for the 80th anniversary of the company's founding), with a payout ratio of 48.3%. For FY2027 (ending March 2027), an annual dividend of ¥170 (interim ¥105 + year-end ¥65) is planned. Under the 5-year medium-term plan "Beyond 80," total dividends of ¥27.0 billion and total share buybacks of ¥30.0 billion (approximately ¥6.0 billion annually) are planned.
Dividend Policy
The basic policy is to maintain stable dividends, aiming for a payout ratio of 40% or more while implementing progressive dividends (ordinary dividends). Dividends are paid twice a year, interim and year-end. Under the 5-year medium-term management plan "Beyond 80," total dividends of ¥27.0 billion are planned. To mark the 80th anniversary of the company's founding, a commemorative dividend of ¥40 per share will be paid in two installments during fiscal 2026: the year-end dividend for FY2026 (ending March 2026) and the interim dividend for FY2027 (ending March 2027).
ESG
The company has conducted climate change scenario analysis (1.5°C and 4°C scenarios) based on the TCFD framework, setting targets of a 42% reduction in CO2 emissions by FY2030 versus FY2020 and carbon neutrality by 2050. In terms of human capital, the company has set forth
Last updated: June 22, 2026